

# Dongli Yue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10265109/publications.pdf>

Version: 2024-02-01

32  
papers

1,560  
citations

471509

17  
h-index

434195

31  
g-index

35  
all docs

35  
docs citations

35  
times ranked

2761  
citing authors

#	ARTICLE	IF	CITATIONS
1	CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β <sup>2</sup> -mTOR-HIF-1 signaling in patients with non-small cell lung cancer. <i>Oncolmmunology</i> , 2017, 6, e1320011.	4.6	205
2	Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer. <i>Cancer Research</i> , 2018, 78, 1779-1791.	0.9	202
3	Cancer-cell-secreted CXCL11 promoted CD8 <sup>+</sup> T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. , 2019, 7, 42.		122
4	Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. <i>Cancer Letters</i> , 2019, 452, 244-253.	7.2	120
5	Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. <i>Oncotarget</i> , 2015, 6, 33961-33971.	1.8	113
6	Low-Dose IFN <sup>β</sup> Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 3737-3748.	0.9	89
7	Inhibition of SALL4 reduces tumorigenicity involving epithelial-mesenchymal transition via Wnt/β <sup>2</sup> -catenin pathway in esophageal squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 98.	8.6	75
8	Dual TGF-β <sup>1</sup> and PD-1 blockade synergistically enhances MAGE-A3-specific CD8 <sup>+</sup> T cell response in esophageal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 2561-2574.	5.1	68
9	Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. <i>Oncolmmunology</i> , 2018, 7, e1442167.	4.6	67
10	Impaired T cell function in malignant pleural effusion is caused by TGF-β <sup>2</sup> derived predominantly from macrophages. <i>International Journal of Cancer</i> , 2016, 139, 2261-2269.	5.1	62
11	miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 86592-86603.	1.8	60
12	Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity. <i>Oncology Reports</i> , 2015, 33, 425-432.	2.6	44
13	Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. <i>Cancer Letters</i> , 2015, 362, 192-198.	7.2	44
14	Transforming growth factor-beta1 promotes the migration and invasion of sphere-forming stem-like cell subpopulations in esophageal cancer. <i>Experimental Cell Research</i> , 2015, 336, 141-149.	2.6	38
15	MicroRNA-202 inhibits tumor progression by targeting LAMA1 in esophageal squamous cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 821-827.	2.1	35
16	Maelstrom Directs Myeloid-Derived Suppressor Cells to Promote Esophageal Squamous Cell Carcinoma Progression via Activation of the Akt1/RelA/IL8 Signaling Pathway. <i>Cancer Immunology Research</i> , 2018, 6, 1246-1259.	3.4	28
17	Epigenetic inactivation of SPINT2 is associated with tumor suppressive function in esophageal squamous cell carcinoma. <i>Experimental Cell Research</i> , 2014, 322, 149-158.	2.6	27
18	Pseudomonas aeruginosa -mannose sensitive hemagglutinin injection treated cytokine-induced killer cells combined with chemotherapy in the treatment of malignancies. <i>International Immunopharmacology</i> , 2017, 51, 57-65.	3.8	19

#	ARTICLE	IF	CITATIONS
19	Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2019, 112, 108632.	5.6	19
20	Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood. <i>Cytotherapy</i> , 2015, 17, 86-97.	0.7	18
21	CLC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma. <i>Cell Death and Disease</i> , 2020, 11, 898.	6.3	13
22	Musashi1, a potential prognostic marker in esophageal squamous cell carcinoma. <i>Oncology Reports</i> , 2017, 38, 1724-1732.	2.6	12
23	NEDD9 promotes cancer stemness by recruiting myeloid-derived suppressor cells &via& CXCL8 in esophageal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 705-720.	3.0	12
24	Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 299-308.	4.2	11
25	Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3513-28.	0.5	11
26	Polarization of granulocytic myeloid-derived suppressor cells by hepatitis C core protein is mediated via IL-10/STAT3 signalling. <i>Journal of Viral Hepatitis</i> , 2019, 26, 246-257.	2.0	10
27	Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 311.	2.8	10
28	Correlation between the high expression levels of cancer-germline genes with clinical characteristics in esophageal squamous cell carcinoma. <i>Histology and Histopathology</i> , 2017, 32, 793-803.	0.7	8
29	Dynamic changes in CD45RA <sup>+</sup> Foxp3 <sup>high</sup> regulatory T-cells in chronic hepatitis C patients during antiviral therapy. <i>International Journal of Infectious Diseases</i> , 2016, 45, 5-12.	3.3	7
30	High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation. <i>Cancer Immunology Research</i> , 2022, 10, 844-855.	3.4	4
31	Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 7446-56.	1.3	2
32	Immunotherapy targeting esophageal cancer stem cells. , 2013, 1, P178.		0